Lineage Cell Therapeutics, Inc. (LCTX)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Brian M. Culley
Employees:
60
2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008
5105213390

OpRegen, a retinal pigment epithelium cell replacement therapy, is in Phase I/IIa clinical trial for the treatment of dry age-related macular degeneration. OPC1, an oligodendrocyte progenitor cell therapy, and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, are in clinical trials to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product.

Data derived from most recent annual or quarterly report
Market Cap 71.813 Million Shares Outstanding57.45 Million Avg 30-day Volume 384.27 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS
Price to Revenue13.7474 Debt to Equity0.0005 EBITDA-46.724 Million
Price to Book Value2.4302 Operating Margin-316.1293 Enterprise Value124.149 Million
Current Ratio3.013 EPS Growth0 Quick Ratio2.937
1 Yr BETA 0.9603 52-week High/Low 2.71 / 1.02 Profit Margin-352.4147
Operating Cash Flow Growth114.9556 Altman Z-Score-2.3328 Free Cash Flow to Firm 12.375 Million
View SEC Filings from LCTX instead.

View recent insider trading info

Funds Holding LCTX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding LCTX

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-11-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-31:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-10-28:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
  • 8-K/A: filed on 2022-09-30:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-09-26:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2022-08-11:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-07:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-17:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-12:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-12:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    HOWE JILL ANN CHIEF FINANCIAL OFFICER

    • Officer
    0 2022-11-14 2

    HERNANDEZ ALEXANDRA SR DIRECTOR FINANCE/CONTROLLER

    • Officer
    0 2022-07-07 1

    BAILEY DON M

    • Director
    50,000 2022-07-01 1

    KINGSLEY ALFRED D

    • Director
    50,000 2022-07-01 2

    BRADSHER NEAL C

    • Director
    • 10% Owner
    189,440 2022-07-01 1

    ANDREWS DEBORAH J

    • Director
    50,000 2022-07-01 1

    MULROY MICHAEL H.

    • Director
    50,000 2022-07-01 2

    RUSSELL ANGUS C.

    • Director
    50,000 2022-07-01 1

    JAYASURIYA ANULA

    • Director
    50,000 2022-07-01 1

    AMIN DIPTI

    • Director
    50,000 2022-07-01 2

    CULLEY BRIAN M PRESIDENT AND CEO

    • Officer
    • Director
    107,894 2022-06-30 6

    BROADWOOD PARTNERS, L.P.

    BROADWOOD CAPITAL INC

    BRADSHER NEAL C

    • Director
    • 10% Owner
    69,870,970 2022-03-23 1

    HOGGE GARY S. SVP,CLINICAL & MEDICAL AFFAIRS

    • Officer
    450,000 2022-03-10 3

    COOK KEVIN LEON CHIEF FINANCIAL OFFICER

    • Officer
    650,000 2022-03-10 2

    SAMUEL GEORGE A. III GENERAL COUNSEL/SECRETARY

    • Officer
    650,000 2022-03-10 2

    LEAVITT CHASE C. GENERAL COUNSEL/SECRETARY

    • Officer
    699,100 2021-03-15 0

    FARRELL STEPHEN C

    • Director
    40,000 2020-07-01 0

    ROBERTS BRANDI CFO & SVP FINANCE

    • Officer
    616,700 2020-03-17 0

    WIRTH EDWARD CHIEF MEDICAL OFFICER

    • Officer
    350,000 2019-03-19 0

    SKIBSTED RUSSELL CHIEF FINANCIAL OFFICER

    • Officer
    35,328 2018-12-18 0

    PATTON STEPHANA EILENE GENERAL COUNSEL & SECRETARY

    • Officer
    48,235 2018-12-18 0

    WEST MICHAEL D CO-CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    No longer subject to file 2018-09-17 0

    MOHANTY ADITYA P. CO-CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    134,197 2018-07-10 0

    REDMOND CAVAN M.

    • Director
    100,000 2018-07-01 0

    GREENBELT CORP /NY

    • SEE REMARKS
    1,043,346 2017-12-31 0

    SCHLACHET DAVID

    • Director
    132,050 2017-07-01 0

    SEGALL JUDITH VICE PRESIDENT & SECRETARY

    • Officer
    666,245 2016-12-31 0

    KNIGHT JAMES A. SR VP, HEAD OF CORPORATE DEV

    • Officer
    17,036 2016-10-19 0

    PEABODY ROBERT SR. VP AND CFO

    • Officer
    515,777 2015-07-10 0

    CARTT STEPHEN LAHUE

    • Director
    120,125 2015-07-01 0

    TEW WILLIAM P PHD

    • FORMER CCO
    No longer subject to file 2015-01-01 0

    LICHTINGER PEDRO

    • Director
    216,250 2014-07-01 0

    STOLZ LESLEY A. EVP, CORPORATE DEVELOPMENT

    • Officer
    250,000 2014-03-20 0

    NORDHOFF HENRY L

    • Director
    40,000 2013-07-01 0

    BERGER FRANKLIN M

    • Director
    40,000 2013-07-01 0

    VON ESCHENBACH ANDREW C.

    • Director
    40,000 2013-07-01 0

    GARCIA PETER S CHIEF FINANCIAL OFFICER

    • Officer
    307,000 2013-02-20 0

    GREENWAY PARTNERS L P

    • 10% Owner
    375,351 2012-12-14 0

    BURNS ARNOLD I

    • Director
    55,000 2012-07-01 0

    COHEN ABRAHAM E

    • Director
    50,000 2012-07-01 0

    DUBERSTEIN GARY K

    • FORMER 10% OWNER
    No longer subject to file 2010-10-22 0

    SEINBERG STEVEN A CHIEF FINANCIAL OFFICER

    • Officer
    22,500 2010-09-01 0

    GREGG VALETA A

    • Director
    34,298 2010-05-12 0

    KARFUNKEL GEORGE

    • 10% Owner
    4,997,217 2010-05-07 0

    STERNBERG HAL VICE PRESIDENT

    • Officer
    No longer subject to file 2009-12-31 0

    WAITZ HAROLD D VICE PRESIDENT

    • Officer
    No longer subject to file 2009-12-31 0

    BUTLER ROBERT N

    • Director
    55,000 2009-12-31 0

    FUNK WALTER D VP FOR STEM CELL RESEARCH

    • Officer
    275,000 2009-12-31 0

    NICKEL JEFFREY B VICE PRESIDENT

    • Officer
    453,749 2006-11-24 0

    GORDON KATHERINE

    • Director
    125,000 2006-03-28 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    HOWE JILL ANN - Officer CHIEF FINANCIAL OFFICER

    2022-11-16 16:17:31 -0500 2022-11-14 A 1,000,000 a 1,000,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    LINEAGE CELL THERAPEUTICS IN LCTX 2022-12-09 20:15:04 UTC -0.834 4.654 2000000
    LINEAGE CELL THERAPEUTICS IN LCTX 2022-12-09 19:45:04 UTC -0.834 4.654 2000000
    LINEAGE CELL THERAPEUTICS IN LCTX 2022-12-09 19:15:04 UTC -0.834 4.654 2000000
    LINEAGE CELL THERAPEUTICS IN LCTX 2022-12-09 18:45:03 UTC -0.834 4.654 2000000
    LINEAGE CELL THERAPEUTICS IN LCTX 2022-12-09 18:15:03 UTC -0.834 4.654 2000000
    LINEAGE CELL THERAPEUTICS IN LCTX 2022-12-09 17:45:03 UTC -0.834 4.654 2000000
    LINEAGE CELL THERAPEUTICS IN LCTX 2022-12-09 17:15:03 UTC -0.834 4.654 2000000
    LINEAGE CELL THERAPEUTICS IN LCTX 2022-12-09 16:45:03 UTC -0.834 4.654 2000000
    LINEAGE CELL THERAPEUTICS IN LCTX 2022-12-09 16:15:03 UTC -0.834 4.654 2000000
    LINEAGE CELL THERAPEUTICS IN LCTX 2022-12-09 15:45:03 UTC -0.834 4.654 2000000
    LINEAGE CELL THERAPEUTICS IN LCTX 2022-12-09 15:15:03 UTC -0.834 4.654 2000000
    LINEAGE CELL THERAPEUTICS IN LCTX 2022-12-09 14:45:04 UTC -0.834 4.654 2000000
    LINEAGE CELL THERAPEUTICS IN LCTX 2022-12-09 14:15:03 UTC -0.834 4.654 2000000
    LINEAGE CELL THERAPEUTICS IN LCTX 2022-12-09 13:45:03 UTC 0.524 3.296 2000000
    LINEAGE CELL THERAPEUTICS IN LCTX 2022-12-09 13:15:03 UTC 0.524 3.296 2000000
    LINEAGE CELL THERAPEUTICS IN LCTX 2022-12-09 12:45:03 UTC 0.524 3.296 2000000
    LINEAGE CELL THERAPEUTICS IN LCTX 2022-12-08 22:15:03 UTC 0.524 3.296 2000000
    LINEAGE CELL THERAPEUTICS IN LCTX 2022-12-08 21:45:04 UTC 0.9673 2.8527 2000000
    LINEAGE CELL THERAPEUTICS IN LCTX 2022-12-08 21:15:03 UTC 0.9673 2.8527 2000000
    LINEAGE CELL THERAPEUTICS IN LCTX 2022-12-08 20:45:04 UTC 0.9673 2.8527 2000000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments